Such moves have increased concerns about investors piling into the Chinese biotech push and also highlights concerns with regards to valuations in a sector that still faces drug development risk.
Such moves have increased concerns about investors piling into the Chinese biotech push and also highlights concerns with regards to valuations in a sector that still faces drug development risk.